FAKTOR ZERTIFIKAT LONG - ASTRAZENECA | Real-time Borsa Italiana 08:09:15 2024-05-23 am EDT | ||
| 40.22 EUR | +9.89% |
|
| Current month | +5.11% | ||
| 1 month | +36.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 40.22 | +9.89% |
| 24-05-22 | 36.6 | -9.34% |
| 24-05-21 | 40.37 | +15.67% |
| 24-05-20 | 34.9 | -2.02% |
| 24-05-17 | 35.62 | -1.60% |
Real-time Borsa Italiana
Last update May 23, 2024 at 08:09 am EDT
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| SAZNL5 | |
| ISIN | DE000SW8FX82 |
| Date issued | 2024-04-08 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.75 € |
|---|---|
| Lowest since issue | 19.05 € |
| Spread | 0.15 € |
| Spread % | 0.37% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.3
USD
Average target price
169.7
USD
Spread / Average Target
+7.87%
- Stock Market
- Certificates
- SAZNL5 Certificat
